TriangleHEALTH PROFESSIONAL · SOURCE READING
Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Metastatic Breast Cancer
Continue within this section
Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy →Mammalian target of rapamycin (mTOR) inhibitor therapy plus endocrine therapy →AKT inhibitor therapy →Alpelisib plus endocrine therapy →Elacestrant →HDAC inhibitor therapy →Endocrine therapy alone →Sequencing therapy for hormone receptor–positive metastatic breast cancer →Sacituzumab govitecan →Chemotherapy →
Preserved source evidence · Not medical advice